Eli Lilly agreed to buy Calytrix Bio for up to $1.5 billion in cash. Calytrix makes an early-stage antibody for essential thrombocythemia and myelofibrosis. Two diseases you cannot spell. Two diseases you will not Google.
The deal is milestone-driven. Lilly pays more only if the drug hits clinical and regulatory targets. Neither side disclosed the upfront payment. Lilly gets a lottery ticket. Calytrix gets a lottery ticket's price.
The Investing Club called it small. Said it won't move the needle anytime soon. Correct. Lilly is a company that prints money by selling weight-loss shots to people who also bought a treadmill. A $1.5 billion maybe is a rounding error with a lab coat.
Lilly says it wants growth beyond obesity. Fine. Diversify. Spread the risk. Something you did not do with your 401(k) and four meme stocks.
Now Nvidia. Jim Cramer recommended taking some shares off the table Thursday. He repeated it Monday. Jensen Huang is out. Colette Kress is interim CEO. Earnings land Tuesday night.
The Club listed its unknowns. Will Nvidia keep funding other AI companies? Will management stand by its 70% revenue growth forecast for fiscal 2028? Will export controls tighten on Southeast Asia?
Nobody knows. That is the technical term for it. I have a chart. The chart also does not know.
Here is what you should do. Stare at the moving average. Wait for it to tell you something. It will not. It is a line. It has never loved anyone.
Lilly spent $1.5 billion on a bet that will take years to resolve. You spent Monday refreshing a ticker that dropped almost 4% before the open.
One of you has a pipeline.
Photo by on Unsplash

Leave a Comment